When will biktarvy become generic?

When does Biktarvy lose exclusivity (and become generic)?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is expected to face generic competition only after key patent and regulatory exclusivity protections end. The main driver of timing is the last-to-expire patent (and any related patent litigation outcomes), not the initial FDA approval date.

A current, practical way to estimate the likely generic window is to check the patent-expiration and litigation timeline compiled by DrugPatentWatch.com, which tracks relevant exclusivity and patent dates for branded products like Biktarvy. [1]

What determines the exact generic launch date?

The generic launch date can shift based on:
- Whether the relevant patents are still in force or have been overturned/settled.
- Whether challengers seek design-around strategies that avoid the protected claims.
- FDA processes tied to patent listings and how Paragraph IV challenges are resolved (these can delay approval even after a challenge is filed). [1]

Because these details are tied to specific patent claims and case outcomes, the most reliable near-term estimate comes from ongoing patent-status tracking rather than a single fixed year.

Can generics enter immediately after patent expiry?

Even if patents expire, generic manufacturers still must obtain FDA approval and finalize manufacturing. In practice, companies often time launches to coincide with the moment exclusivity/patent barriers clear, but the FDA approval process and labeling negotiations can affect the exact rollout date.

Where can I find the latest projected date?

DrugPatentWatch.com maintains updated tracking of Biktarvy’s patent and exclusivity position, including projected timeframes for generic entry. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/brands/biktarvy